Description

GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide that stimulates growth hormone secretion through the ghrelin receptor. As one of the earliest growth hormone secretagogues developed, GHRP-6 has accumulated decades of research data — giving it one of the most robust safety and efficacy profiles in the peptide literature.

Research Profile

GHRP-6 triggers GH release through a mechanism distinct from GHRH — binding to the growth hormone secretagogue receptor (GHS-R1a) in the pituitary and hypothalamus. It produces a strong, rapid GH pulse within 15-30 minutes of administration in research models. Notable characteristic: GHRP-6 also stimulates appetite through ghrelin pathway activation, which differentiates it from more selective secretagogues like Ipamorelin.

Key Research Areas

Robust growth hormone release (dose-dependent)
Appetite stimulation via ghrelin receptor activation
Cardioprotective effects in ischemia models
Cortisol and prolactin modulation at higher doses
Cytoprotective properties in gastric tissue

Specifications

Sequence	His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂
Molecular Weight	873.01 g/mol
Purity	≥99% (HPLC verified)
Form	Lyophilized powder
Quantity	5mg per vial
Storage	-20°C pre-reconstitution

Related Research Peptides

Compare GHRP-6 with the more selective Ipamorelin, or explore the GHRH side with CJC-1295. Full comparison in our muscle growth peptides guide.

Research Dosage Protocols

GHRP-6 is typically studied at 100–300mcg per injection in animal GH research models, with administration 2–3 times daily due to its 2–3 hour half-life. The appetite stimulation effect appears within 30 minutes of administration, which is relevant for metabolic research timing. A 5mg vial reconstituted in 2mL bacteriostatic water yields 2,500mcg/mL. Research protocols using GHRP-6 in combination with a GHRH analog (most commonly CJC-1295) show additive GH release at these doses. Cortisol elevation is documented at doses above 1mcg/kg in some species, so protocols measuring GH in isolation should note ACTH/cortisol as a confounding variable.

Frequently Asked Questions

Why does GHRP-6 increase appetite, and what’s the mechanism?

GHRP-6’s appetite stimulation comes directly from its ghrelin-mimetic activity. Ghrelin is the endogenous ligand for GHSR-1a — the “hunger hormone” released from the stomach before meals. GHRP-6 was designed to mimic ghrelin’s GH-releasing effects, but it also inherited ghrelin’s appetite-stimulating properties because it activates the same receptor. The GHSR-1a receptor in the hypothalamus regulates energy balance and feeding behavior. At research doses, GHRP-6 produces significant appetite stimulation within 20–30 minutes of administration — strong enough that metabolic studies use this as a measurable endpoint in its own right.

At what doses does cortisol elevation become significant in GHRP-6 research?

Cortisol elevation with GHRP-6 is dose-dependent. At lower doses (around 0.1–0.3mcg/kg), GH release occurs with minimal ACTH/cortisol response in most rodent models. As doses climb above 1mcg/kg, measurable cortisol elevation appears — the mechanism involves GHRP-6 stimulating ACTH secretion from corticotroph cells in the pituitary, separate from its GHSR-1a activity. This is a meaningful confounder for long-term studies because chronic cortisol elevation can independently affect body composition, immune function, and metabolic markers that researchers may incorrectly attribute to GH. Researchers isolating GH effects should track cortisol as a secondary variable.

How does GHRP-6 compare to Ipamorelin for GH secretagogue research?

GHRP-6 is a more potent GH releaser than Ipamorelin at equivalent doses, but produces more off-target effects — cortisol, prolactin, and appetite stimulation all exceed Ipamorelin’s profile. This makes GHRP-6 less appropriate when GH is the sole variable being studied, but more useful when the study design specifically incorporates ghrelin-pathway activation and its downstream metabolic consequences. For pure GH secretagogue research with minimal confounds, Ipamorelin is cleaner. For research studying ghrelin receptor biology, appetite regulation, or the full spectrum of GHSR-1a effects, GHRP-6’s broader activity profile is actually an advantage.

What’s the best administration timing for GHRP-6 in GH research?

Like all GHRPs, GHRP-6 produces larger GH responses when somatostatin tone is low. Fasting states (before meals, or in animals during the light phase for nocturnal species) reduce somatostatin, amplifying the GH pulse triggered by GHSR-1a activation. Administration timing 45–90 minutes before sacrifice or blood collection in acute studies captures the peak GH elevation. For multi-dose protocols, space administrations 4–6 hours apart to allow somatostatin levels to reset and avoid blunting subsequent pulses. Avoid dosing immediately post-meal in studies where consistent GH response amplitude is important.

Does food timing around GHRP-6 administration affect results?

Yes — significantly. Elevated blood glucose and insulin following a meal increase somatostatin release, which inhibits GH secretion at the pituitary level. GHRP-6 can still trigger GHSR-1a activation in a fed state, but the resulting GH pulse is substantially blunted by elevated somatostatin. Research studies requiring consistent, reproducible GH responses use fasted conditions (typically 2–4 hours post-meal in rodents). GHRP-6’s appetite effect also means animals may eat immediately after dosing — in studies where post-dose food intake must be controlled, this needs to be factored into the experimental design.

Can GHRP-6 be combined with CJC-1295 in research protocols?

Yes — GHRP-6 and CJC-1295 (or any GHRH analog) produce synergistic GH release through the same two-receptor mechanism as the Ipamorelin/CJC-1295 combination. CJC-1295 primes somatotroph cells via GHRH receptors; GHRP-6 triggers release via GHSR-1a. The combination amplifies GH output 2–3x compared to either peptide alone. The key consideration when substituting GHRP-6 for Ipamorelin in a GHRH/GHRP combination protocol is that cortisol and appetite effects will be more pronounced. This may be irrelevant to the study question — or it may require additional controls depending on what outcomes are being measured.

For research and laboratory use only. Not for human consumption. All peptides are sold strictly as research chemicals.

GHRP-6